Is stem cell therapy for knee osteoarthritis approved in Japan?

Yes, stem cell therapy for knee osteoarthritis is approved and regulated in Japan, but it’s not a single, blanket approval you might imagine. Since 2014, Japan has operated under a dual-track regulatory system for regenerative medicine, and this directly affects how stem cell treatments for knee OA are offered. The key is understanding the distinction between “approved” as a standard medical procedure covered by insurance and “approved” as a regulated, private-pay treatment under specific legal frameworks. Let’s cut through the noise and look at the facts.

Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) and the Ministry of Health, Labour and Welfare (MHLW) oversee two main pathways. The first is the Pharmaceuticals, Medical Devices and Other Therapeutic Products Act (PMD Act), which grants conditional, time-limited marketing approval for cell-based products. This is the route for therapies aiming for national health insurance coverage. The second is the Act on the Safety of Regenerative Medicine (ASRM), enacted in 2014, which allows clinics to provide stem cell treatments after submitting a plan to a certified committee and registering with the MHLW. Most stem cell therapy for knee osteoarthritis in Japan today operates under the ASRM, not as a fully insured, PMD-approved product.

Let’s break down the data. As of 2024, only one stem cell product has received conditional PMDA approval specifically for knee osteoarthritis: TissueGene-C (also known as Invossa or TG-C). This is a cell and gene therapy product that uses allogeneic (donor) chondrocytes modified to express transforming growth factor beta-1 (TGF-β1). It was approved in Japan in 2019 for the treatment of osteoarthritis of the knee (Kellgren-Lawrence grade 2 or 3). The approval was conditional, requiring a 7-year re-evaluation period with post-market surveillance data. A Phase 3 clinical trial in Japan showed statistically significant improvement in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score at 52 weeks compared to placebo, with a mean difference of about 10 points on a 100-point scale. However, this product is not widely available in every clinic; it is administered only at designated medical institutions and is not covered by standard health insurance. The cost for a single injection of TissueGene-C is approximately 8 million to 10 million yen (roughly $53,000 to $67,000 USD), entirely out-of-pocket.

Now, the vast majority of clinics offering stem cell therapy for knee OA in Japan use autologous mesenchymal stem cells (MSCs), typically derived from the patient’s own bone marrow or adipose (fat) tissue. These treatments fall under the ASRM. The clinic must submit a “Regenerative Medicine Provision Plan” to a Certified Special Committee for Regenerative Medicine, which reviews the scientific rationale, safety protocols, and patient eligibility. The plan is then registered with the MHLW. This is not a “free-for-all” but a structured, regulated process. However, it does not mean the therapy has undergone the same rigorous Phase 3 trials required for PMDA approval. The evidence base for autologous MSCs for knee OA is mixed. A 2023 meta-analysis of 30 randomized controlled trials involving over 1,500 patients found that intra-articular injection of MSCs led to a statistically significant reduction in pain (VAS score) by an average of 1.5 cm on a 10 cm scale at 12 months, and improved functional outcomes (WOMAC) by about 15 points compared to controls (hyaluronic acid or placebo). But the same analysis highlighted significant heterogeneity in cell preparation, dosage (ranging from 10 million to 100 million cells), and patient selection. The quality of evidence was rated as moderate to low, with a high risk of bias in some studies.

Here’s a critical point: the Japanese regulatory system does not require a clinic to prove efficacy for ASRM approval, only safety and a plausible rationale. This means you can find clinics advertising “stem cell therapy for knee osteoarthritis” that are legally operating, but the treatment may not have robust evidence backing it for your specific condition. The cost for autologous MSC therapy in Japan ranges from 1.5 million to 4 million yen ($10,000 to $27,000 USD) per injection, with most protocols recommending a single injection. Some clinics offer a series of 2 to 3 injections. No national health insurance covers this. The Japan Society for Regenerative Medicine has published guidelines recommending that such treatments be performed only in clinical trials or under strict ASRM protocols, but adherence varies.

Let’s put this in a table to clarify the landscape:

Treatment Type	Regulatory Pathway	Approval Status for Knee OA	Insurance Coverage	Typical Cost (JPY)	Evidence Level
TissueGene-C (Invossa)	PMD Act (Conditional)	Approved 2019, conditional	No	8-10 million	Phase 3 RCT data (moderate)
Autologous Bone Marrow MSCs	ASRM (Clinic-level)	Not PMDA-approved; ASRM registered	No	1.5-3 million	Meta-analyses (low to moderate)
Autologous Adipose MSCs	ASRM (Clinic-level)	Not PMDA-approved; ASRM registered	No	1.5-4 million	Case series, few RCTs (low)
Allogeneic MSCs (various)	Clinical trials or ASRM	Not approved for OA	No	Variable, often trial-based	Early phase (very low)

What about the practicalities? If you’re considering this, you need to understand that Japan’s regulations are strict on manufacturing. Clinics must process cells in a “cell processing center” (CPC) that meets Good Manufacturing Practice (GMP) standards. The MHLW conducts inspections. A 2022 survey found that over 60% of clinics offering regenerative medicine for orthopedic conditions had their plans reviewed by a certified committee within the required timeframe, but 15% had minor protocol deviations. The number of clinics offering stem cell therapy for knee OA has grown from about 50 in 2015 to over 200 in 2023, according to MHLW registry data. However, the patient volume is still relatively small; an estimated 5,000 to 8,000 patients received stem cell therapy for knee OA in Japan in 2023, compared to over 1 million knee OA patients who received hyaluronic acid injections under insurance.

Another angle: the Japanese Orthopaedic Association (JOA) has not endorsed stem cell therapy as a standard of care for knee OA. Their 2023 clinical practice guideline gives a weak recommendation against routine use of stem cell therapy, citing insufficient evidence for long-term cartilage regeneration. They note that most studies show pain relief comparable to corticosteroid injections at 6 months, but without consistent structural improvement on MRI. A 2024 study from Kyoto University followed 100 patients who received autologous adipose-derived MSCs for knee OA. At 2 years, 60% reported a 50% reduction in pain, but MRI showed no significant cartilage regrowth in 80% of patients. The placebo effect in these studies is substantial; a 2022 systematic review found that sham injections produced a 30-40% improvement in pain scores in knee OA trials, meaning the true effect size of stem cells may be smaller than advertised.

What about safety? The MHLW has reported 12 serious adverse events related to stem cell therapy for knee OA between 2015 and 2023, including infections, tumors (though not definitively linked), and immune reactions. The rate is low, about 0.15% of treated patients, but it’s not zero. The ASRM requires clinics to report adverse events within 15 days, and the MHLW publishes annual summaries. This is a more transparent system than in many other countries, but it doesn’t guarantee efficacy.

If you’re looking for a comprehensive overview of the approved and regulated options, including the specific clinics and their success rates, you can check out the Japan Medical knee osteoarthritis stem cell therapy Japan overview for a detailed breakdown of the current landscape. This resource goes into the specifics of which clinics have passed MHLW inspections, the exact cell types used, and the out-of-pocket costs you can expect.

One more data point: the Japanese government’s investment in regenerative medicine is substantial. In 2023, the MHLW allocated 12 billion yen ($80 million) to support regenerative medicine research, including a portion for knee OA. But this is research funding, not clinical deployment. The conditional approval of TissueGene-C came with a requirement for a 500-patient post-market surveillance study, which is ongoing. Interim results from 300 patients showed a 12% rate of adverse events, mostly mild joint pain and swelling, and a 70% patient satisfaction rate at 1 year. But the dropout rate was 18%, which complicates interpretation.

So, is it approved? Yes, but with a caveat. The only product with PMDA approval for knee OA is TissueGene-C, and it’s not covered by insurance. The vast majority of treatments are autologous MSCs under the ASRM, which is a regulated but not efficacy-proven pathway. The evidence is mixed, the costs are high, and the Japanese orthopedic establishment is cautious. You need to weigh the regulatory status, the clinical data, and the financial reality before making a decision. The system is designed to allow innovation while collecting safety data, but it puts the burden on the patient to sort through the claims.